Funding for this research was provided by:
Gilead Sciences (IN-US-987-6016)
Received: 3 April 2023
Accepted: 6 August 2023
First Online: 17 August 2023
: This first phase of the Erase Hep C study was approved by the University of Texas at Austin’s Institutional Review Board, as well as CommUnityCare’s Research and Quality Improvement Committee. Written voluntary informed consent was obtained from study participants for the qualitative interviews.
: Not applicable.
: The authors declare no competing interests.